Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;15(Suppl 3):501-508.
doi: 10.1007/s13193-024-02032-7. Epub 2024 Jul 29.

Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Impact on Early Stage and Outcomes-Comprehensive Review

Raxith Sringeri R  1
Affiliations
Review

Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Impact on Early Stage and Outcomes-Comprehensive Review

Raxith Sringeri R. Indian J Surg Oncol. 2024 Sep.

Abstract

Triple-negative breast cancer (TNBC) poses a significant challenge in clinical oncology due to its aggressive nature and limited targeted therapeutic options. Neoadjuvant chemotherapy (NACT) has emerged as a promising strategy in the management of early-stage TNBC. This literature review aims to provide an in-depth analysis of the role of NACT in TNBC, focusing on its impact on early-stage disease and associated outcomes. The review synthesizes evidence from recent studies, clinical trials, and meta-analyses to present a comprehensive overview of the current landscape of NACT in early-stage TNBC.

Keywords: BCS; Breast cancer; Early breast cancer; Immunotherapy; NACT; TNBC.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe author declares no competing interests.

Figures

Fig. 1
Fig. 1
Treatment algorithm for early-stage triple-negative breast cancer. ddAC-T, dose-dense doxorubicin and cyclophosphamide followed by paclitaxel; gBRCA, germline BRCA mutation; pCR, pathologic complete response; RD, residual disease; TC, docetaxel and cyclophosphamide; TCb, paclitaxel and carboplatin
See this image and copyright information in PMC

References

    1. von Minckwitz G, Schneeweiss A, Loibl S et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 15(7):747–756 - PubMed
    1. Masuda N, Lee SJ, Ohtani S et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 376(22):2147–2159 - PubMed
    1. Sikov WM, Berry DA, Perou CM et al (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 33(1):13–21 - PMC - PubMed
    1. Carey LA, Rugo HS, Marcom PK et al (2012) TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 30(21):2615–2623 - PMC - PubMed
    1. Hylton NM, Blume JD, Bernreuter WK et al (2012) Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL. Radiology 263(3):663–672 - PMC - PubMed

LinkOut - more resources